[Prophylaxis of superficial tumors of the bladder with interferon alfa-2B].
The AA. report the results obtained on patients suffering from surface bladder cancer [Ta-T1 (G1-G2)] treated with alpha 2b interferon with the aim to elongate the relapse period. The results turned out to be very satisfactory as concerns the tolerability of the drug as well as the actual improvement in relapse onset. Moreover, the AA. could notice the grading steadiness or decrease, as to neglistic relapses.
Maffucci
A
A
Divisione di Urologia, U.S.L. 41-Ospedale V. Monaldi, Napoli.
Fico
A
A
Giannella
L
L
Giannella
R
R
D000283:Administration, Intravesical; D000368:Aged; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D009367:Neoplasm Staging; D011994:Recombinant Proteins; D001749:Urinary Bladder Neoplasms / Q000473:pathology / Q000517:prevention & control* / Q000601:surgery
D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins
Profilassi dei tumori superficiali della vescica con interferone alpha 2b.